nodes	percent_of_prediction	percent_of_DWPC	metapath
Salmeterol—CYP3A5—prostate cancer	0.173	0.45	CbGaD
Salmeterol—ADRB2—prostate cancer	0.137	0.356	CbGaD
Salmeterol—CYP3A4—prostate cancer	0.0747	0.195	CbGaD
Salmeterol—CYP2C8—Nilutamide—prostate cancer	0.0346	0.0852	CbGbCtD
Salmeterol—CYP3A5—Flutamide—prostate cancer	0.0298	0.0735	CbGbCtD
Salmeterol—CYP2C8—Abiraterone—prostate cancer	0.0286	0.0706	CbGbCtD
Salmeterol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0267	0.0658	CbGbCtD
Salmeterol—CYP3A5—Cabazitaxel—prostate cancer	0.022	0.0543	CbGbCtD
Salmeterol—CYP3A5—Estrone—prostate cancer	0.0215	0.0531	CbGbCtD
Salmeterol—CYP2C8—Cabazitaxel—prostate cancer	0.0212	0.0522	CbGbCtD
Salmeterol—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0185	0.0455	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.0165	0.0407	CbGbCtD
Salmeterol—CYP3A7—Estradiol—prostate cancer	0.0165	0.0407	CbGbCtD
Salmeterol—CYP3A4—Bicalutamide—prostate cancer	0.014	0.0346	CbGbCtD
Salmeterol—CYP3A4—Estramustine—prostate cancer	0.013	0.0321	CbGbCtD
Salmeterol—CYP3A5—Estradiol—prostate cancer	0.0124	0.0305	CbGbCtD
Salmeterol—CYP2C8—Estradiol—prostate cancer	0.0119	0.0293	CbGbCtD
Salmeterol—CYP3A4—Flutamide—prostate cancer	0.0116	0.0286	CbGbCtD
Salmeterol—CYP3A4—Abiraterone—prostate cancer	0.0116	0.0286	CbGbCtD
Salmeterol—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00985	0.0243	CbGbCtD
Salmeterol—CYP3A7—Docetaxel—prostate cancer	0.00985	0.0243	CbGbCtD
Salmeterol—CYP3A4—Cabazitaxel—prostate cancer	0.00859	0.0212	CbGbCtD
Salmeterol—CYP3A4—Estrone—prostate cancer	0.0084	0.0207	CbGbCtD
Salmeterol—CYP3A5—Etoposide—prostate cancer	0.00808	0.0199	CbGbCtD
Salmeterol—CYP2C8—Etoposide—prostate cancer	0.00777	0.0192	CbGbCtD
Salmeterol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00749	0.0185	CbGbCtD
Salmeterol—CYP3A5—Docetaxel—prostate cancer	0.00739	0.0182	CbGbCtD
Salmeterol—CYP3A4—Conjugated Estrogens—prostate cancer	0.0055	0.0135	CbGbCtD
Salmeterol—CYP3A4—Mitoxantrone—prostate cancer	0.005	0.0123	CbGbCtD
Salmeterol—CYP3A4—Estradiol—prostate cancer	0.00482	0.0119	CbGbCtD
Salmeterol—CYP3A4—Prednisone—prostate cancer	0.00415	0.0102	CbGbCtD
Salmeterol—CYP3A4—Etoposide—prostate cancer	0.00315	0.00777	CbGbCtD
Salmeterol—CYP3A4—Docetaxel—prostate cancer	0.00288	0.00711	CbGbCtD
Salmeterol—CYP3A4—Doxorubicin—prostate cancer	0.00215	0.0053	CbGbCtD
Salmeterol—Arbutamine—ADRB2—prostate cancer	0.000406	0.285	CrCbGaD
Salmeterol—Salbutamol—ADRB2—prostate cancer	0.000394	0.277	CrCbGaD
Salmeterol—Labetalol—ADRB2—prostate cancer	0.000288	0.202	CrCbGaD
Salmeterol—Salbutamol—CYP3A4—prostate cancer	0.000216	0.151	CrCbGaD
Salmeterol—Propafenone—CYP3A4—prostate cancer	0.000121	0.0846	CrCbGaD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	4.7e-05	0.000327	CcSEcCtD
Salmeterol—Cough—Capecitabine—prostate cancer	4.69e-05	0.000327	CcSEcCtD
Salmeterol—Pain—Etoposide—prostate cancer	4.67e-05	0.000325	CcSEcCtD
Salmeterol—Constipation—Etoposide—prostate cancer	4.67e-05	0.000325	CcSEcCtD
Salmeterol—Conjunctivitis—Epirubicin—prostate cancer	4.66e-05	0.000325	CcSEcCtD
Salmeterol—Urinary tract infection—Epirubicin—prostate cancer	4.66e-05	0.000325	CcSEcCtD
Salmeterol—Dizziness—Estradiol—prostate cancer	4.66e-05	0.000324	CcSEcCtD
Salmeterol—Hypertension—Capecitabine—prostate cancer	4.64e-05	0.000324	CcSEcCtD
Salmeterol—Dry mouth—Docetaxel—prostate cancer	4.63e-05	0.000322	CcSEcCtD
Salmeterol—Upper respiratory tract infection—Doxorubicin—prostate cancer	4.63e-05	0.000322	CcSEcCtD
Salmeterol—Chest pain—Capecitabine—prostate cancer	4.58e-05	0.000319	CcSEcCtD
Salmeterol—Myalgia—Capecitabine—prostate cancer	4.58e-05	0.000319	CcSEcCtD
Salmeterol—Arthralgia—Capecitabine—prostate cancer	4.58e-05	0.000319	CcSEcCtD
Salmeterol—Anxiety—Capecitabine—prostate cancer	4.56e-05	0.000318	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	4.55e-05	0.000317	CcSEcCtD
Salmeterol—Oedema—Docetaxel—prostate cancer	4.53e-05	0.000316	CcSEcCtD
Salmeterol—Anaphylactic shock—Docetaxel—prostate cancer	4.53e-05	0.000316	CcSEcCtD
Salmeterol—Discomfort—Capecitabine—prostate cancer	4.52e-05	0.000315	CcSEcCtD
Salmeterol—Epistaxis—Epirubicin—prostate cancer	4.52e-05	0.000315	CcSEcCtD
Salmeterol—Infection—Docetaxel—prostate cancer	4.5e-05	0.000314	CcSEcCtD
Salmeterol—Sinusitis—Epirubicin—prostate cancer	4.5e-05	0.000314	CcSEcCtD
Salmeterol—Feeling abnormal—Etoposide—prostate cancer	4.5e-05	0.000313	CcSEcCtD
Salmeterol—Hyperglycaemia—Doxorubicin—prostate cancer	4.49e-05	0.000313	CcSEcCtD
Salmeterol—Diarrhoea—Mitoxantrone—prostate cancer	4.49e-05	0.000313	CcSEcCtD
Salmeterol—Dry mouth—Capecitabine—prostate cancer	4.48e-05	0.000312	CcSEcCtD
Salmeterol—Vomiting—Estradiol—prostate cancer	4.48e-05	0.000312	CcSEcCtD
Salmeterol—Pneumonia—Doxorubicin—prostate cancer	4.46e-05	0.000311	CcSEcCtD
Salmeterol—Gastrointestinal pain—Etoposide—prostate cancer	4.46e-05	0.000311	CcSEcCtD
Salmeterol—Nervous system disorder—Docetaxel—prostate cancer	4.45e-05	0.00031	CcSEcCtD
Salmeterol—Ill-defined disorder—Prednisone—prostate cancer	4.45e-05	0.00031	CcSEcCtD
Salmeterol—Rash—Estradiol—prostate cancer	4.44e-05	0.000309	CcSEcCtD
Salmeterol—Infestation NOS—Doxorubicin—prostate cancer	4.44e-05	0.000309	CcSEcCtD
Salmeterol—Infestation—Doxorubicin—prostate cancer	4.44e-05	0.000309	CcSEcCtD
Salmeterol—Dermatitis—Estradiol—prostate cancer	4.43e-05	0.000309	CcSEcCtD
Salmeterol—Tachycardia—Docetaxel—prostate cancer	4.43e-05	0.000308	CcSEcCtD
Salmeterol—Headache—Estradiol—prostate cancer	4.41e-05	0.000307	CcSEcCtD
Salmeterol—Skin disorder—Docetaxel—prostate cancer	4.4e-05	0.000307	CcSEcCtD
Salmeterol—Agitation—Prednisone—prostate cancer	4.4e-05	0.000307	CcSEcCtD
Salmeterol—Oedema—Capecitabine—prostate cancer	4.39e-05	0.000306	CcSEcCtD
Salmeterol—Angioedema—Prednisone—prostate cancer	4.38e-05	0.000305	CcSEcCtD
Salmeterol—Infection—Capecitabine—prostate cancer	4.36e-05	0.000304	CcSEcCtD
Salmeterol—Urticaria—Etoposide—prostate cancer	4.33e-05	0.000302	CcSEcCtD
Salmeterol—Malaise—Prednisone—prostate cancer	4.32e-05	0.000301	CcSEcCtD
Salmeterol—Rhinitis—Epirubicin—prostate cancer	4.32e-05	0.000301	CcSEcCtD
Salmeterol—Body temperature increased—Etoposide—prostate cancer	4.31e-05	0.000301	CcSEcCtD
Salmeterol—Abdominal pain—Etoposide—prostate cancer	4.31e-05	0.000301	CcSEcCtD
Salmeterol—Conjunctivitis—Doxorubicin—prostate cancer	4.31e-05	0.000301	CcSEcCtD
Salmeterol—Urinary tract infection—Doxorubicin—prostate cancer	4.31e-05	0.000301	CcSEcCtD
Salmeterol—Nervous system disorder—Capecitabine—prostate cancer	4.31e-05	0.0003	CcSEcCtD
Salmeterol—Tachycardia—Capecitabine—prostate cancer	4.28e-05	0.000299	CcSEcCtD
Salmeterol—Pharyngitis—Epirubicin—prostate cancer	4.27e-05	0.000298	CcSEcCtD
Salmeterol—Skin disorder—Capecitabine—prostate cancer	4.26e-05	0.000297	CcSEcCtD
Salmeterol—Connective tissue disorder—Epirubicin—prostate cancer	4.23e-05	0.000295	CcSEcCtD
Salmeterol—Epistaxis—Doxorubicin—prostate cancer	4.19e-05	0.000292	CcSEcCtD
Salmeterol—Nausea—Estradiol—prostate cancer	4.18e-05	0.000291	CcSEcCtD
Salmeterol—Vomiting—Mitoxantrone—prostate cancer	4.17e-05	0.000291	CcSEcCtD
Salmeterol—Sinusitis—Doxorubicin—prostate cancer	4.16e-05	0.00029	CcSEcCtD
Salmeterol—Hypertension—Prednisone—prostate cancer	4.14e-05	0.000288	CcSEcCtD
Salmeterol—Rash—Mitoxantrone—prostate cancer	4.14e-05	0.000288	CcSEcCtD
Salmeterol—Dermatitis—Mitoxantrone—prostate cancer	4.13e-05	0.000288	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.13e-05	0.000288	CcSEcCtD
Salmeterol—Headache—Mitoxantrone—prostate cancer	4.11e-05	0.000286	CcSEcCtD
Salmeterol—Insomnia—Docetaxel—prostate cancer	4.1e-05	0.000286	CcSEcCtD
Salmeterol—Myalgia—Prednisone—prostate cancer	4.08e-05	0.000284	CcSEcCtD
Salmeterol—Arthralgia—Prednisone—prostate cancer	4.08e-05	0.000284	CcSEcCtD
Salmeterol—Paraesthesia—Docetaxel—prostate cancer	4.07e-05	0.000284	CcSEcCtD
Salmeterol—Anxiety—Prednisone—prostate cancer	4.07e-05	0.000283	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.05e-05	0.000282	CcSEcCtD
Salmeterol—Dyspnoea—Docetaxel—prostate cancer	4.04e-05	0.000282	CcSEcCtD
Salmeterol—Discomfort—Prednisone—prostate cancer	4.03e-05	0.000281	CcSEcCtD
Salmeterol—Hypersensitivity—Etoposide—prostate cancer	4.02e-05	0.00028	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Capecitabine—prostate cancer	4e-05	0.000279	CcSEcCtD
Salmeterol—Cardiac disorder—Epirubicin—prostate cancer	4e-05	0.000278	CcSEcCtD
Salmeterol—Rhinitis—Doxorubicin—prostate cancer	3.99e-05	0.000278	CcSEcCtD
Salmeterol—Dyspepsia—Docetaxel—prostate cancer	3.99e-05	0.000278	CcSEcCtD
Salmeterol—Insomnia—Capecitabine—prostate cancer	3.97e-05	0.000277	CcSEcCtD
Salmeterol—Pharyngitis—Doxorubicin—prostate cancer	3.95e-05	0.000276	CcSEcCtD
Salmeterol—Paraesthesia—Capecitabine—prostate cancer	3.94e-05	0.000275	CcSEcCtD
Salmeterol—Asthenia—Etoposide—prostate cancer	3.91e-05	0.000273	CcSEcCtD
Salmeterol—Connective tissue disorder—Doxorubicin—prostate cancer	3.91e-05	0.000273	CcSEcCtD
Salmeterol—Dyspnoea—Capecitabine—prostate cancer	3.91e-05	0.000273	CcSEcCtD
Salmeterol—Anaphylactic shock—Prednisone—prostate cancer	3.91e-05	0.000273	CcSEcCtD
Salmeterol—Oedema—Prednisone—prostate cancer	3.91e-05	0.000273	CcSEcCtD
Salmeterol—Fatigue—Docetaxel—prostate cancer	3.91e-05	0.000272	CcSEcCtD
Salmeterol—Nausea—Mitoxantrone—prostate cancer	3.9e-05	0.000272	CcSEcCtD
Salmeterol—Immune system disorder—Epirubicin—prostate cancer	3.89e-05	0.000271	CcSEcCtD
Salmeterol—Infection—Prednisone—prostate cancer	3.89e-05	0.000271	CcSEcCtD
Salmeterol—Mediastinal disorder—Epirubicin—prostate cancer	3.88e-05	0.00027	CcSEcCtD
Salmeterol—Constipation—Docetaxel—prostate cancer	3.88e-05	0.00027	CcSEcCtD
Salmeterol—Pain—Docetaxel—prostate cancer	3.88e-05	0.00027	CcSEcCtD
Salmeterol—Dyspepsia—Capecitabine—prostate cancer	3.86e-05	0.000269	CcSEcCtD
Salmeterol—Arrhythmia—Epirubicin—prostate cancer	3.85e-05	0.000268	CcSEcCtD
Salmeterol—Nervous system disorder—Prednisone—prostate cancer	3.84e-05	0.000267	CcSEcCtD
Salmeterol—Tachycardia—Prednisone—prostate cancer	3.82e-05	0.000266	CcSEcCtD
Salmeterol—Skin disorder—Prednisone—prostate cancer	3.8e-05	0.000265	CcSEcCtD
Salmeterol—Fatigue—Capecitabine—prostate cancer	3.79e-05	0.000264	CcSEcCtD
Salmeterol—Mental disorder—Epirubicin—prostate cancer	3.77e-05	0.000263	CcSEcCtD
Salmeterol—Constipation—Capecitabine—prostate cancer	3.75e-05	0.000262	CcSEcCtD
Salmeterol—Pain—Capecitabine—prostate cancer	3.75e-05	0.000262	CcSEcCtD
Salmeterol—Malnutrition—Epirubicin—prostate cancer	3.75e-05	0.000261	CcSEcCtD
Salmeterol—Feeling abnormal—Docetaxel—prostate cancer	3.74e-05	0.00026	CcSEcCtD
Salmeterol—Diarrhoea—Etoposide—prostate cancer	3.73e-05	0.00026	CcSEcCtD
Salmeterol—Gastrointestinal pain—Docetaxel—prostate cancer	3.71e-05	0.000258	CcSEcCtD
Salmeterol—Cardiac disorder—Doxorubicin—prostate cancer	3.7e-05	0.000258	CcSEcCtD
Salmeterol—Tension—Epirubicin—prostate cancer	3.68e-05	0.000256	CcSEcCtD
Salmeterol—Nervousness—Epirubicin—prostate cancer	3.64e-05	0.000254	CcSEcCtD
Salmeterol—Back pain—Epirubicin—prostate cancer	3.62e-05	0.000253	CcSEcCtD
Salmeterol—Feeling abnormal—Capecitabine—prostate cancer	3.62e-05	0.000252	CcSEcCtD
Salmeterol—Dizziness—Etoposide—prostate cancer	3.61e-05	0.000251	CcSEcCtD
Salmeterol—Muscle spasms—Epirubicin—prostate cancer	3.6e-05	0.000251	CcSEcCtD
Salmeterol—Immune system disorder—Doxorubicin—prostate cancer	3.6e-05	0.000251	CcSEcCtD
Salmeterol—Gastrointestinal pain—Capecitabine—prostate cancer	3.59e-05	0.00025	CcSEcCtD
Salmeterol—Mediastinal disorder—Doxorubicin—prostate cancer	3.59e-05	0.00025	CcSEcCtD
Salmeterol—Abdominal pain—Docetaxel—prostate cancer	3.58e-05	0.00025	CcSEcCtD
Salmeterol—Body temperature increased—Docetaxel—prostate cancer	3.58e-05	0.00025	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.56e-05	0.000248	CcSEcCtD
Salmeterol—Arrhythmia—Doxorubicin—prostate cancer	3.56e-05	0.000248	CcSEcCtD
Salmeterol—Insomnia—Prednisone—prostate cancer	3.54e-05	0.000247	CcSEcCtD
Salmeterol—Paraesthesia—Prednisone—prostate cancer	3.51e-05	0.000245	CcSEcCtD
Salmeterol—Mental disorder—Doxorubicin—prostate cancer	3.49e-05	0.000243	CcSEcCtD
Salmeterol—Urticaria—Capecitabine—prostate cancer	3.49e-05	0.000243	CcSEcCtD
Salmeterol—Ill-defined disorder—Epirubicin—prostate cancer	3.48e-05	0.000242	CcSEcCtD
Salmeterol—Abdominal pain—Capecitabine—prostate cancer	3.47e-05	0.000242	CcSEcCtD
Salmeterol—Body temperature increased—Capecitabine—prostate cancer	3.47e-05	0.000242	CcSEcCtD
Salmeterol—Vomiting—Etoposide—prostate cancer	3.47e-05	0.000242	CcSEcCtD
Salmeterol—Malnutrition—Doxorubicin—prostate cancer	3.47e-05	0.000242	CcSEcCtD
Salmeterol—Agitation—Epirubicin—prostate cancer	3.44e-05	0.00024	CcSEcCtD
Salmeterol—Dyspepsia—Prednisone—prostate cancer	3.44e-05	0.00024	CcSEcCtD
Salmeterol—Rash—Etoposide—prostate cancer	3.44e-05	0.00024	CcSEcCtD
Salmeterol—Dermatitis—Etoposide—prostate cancer	3.44e-05	0.00024	CcSEcCtD
Salmeterol—Headache—Etoposide—prostate cancer	3.42e-05	0.000238	CcSEcCtD
Salmeterol—Tension—Doxorubicin—prostate cancer	3.4e-05	0.000237	CcSEcCtD
Salmeterol—Malaise—Epirubicin—prostate cancer	3.38e-05	0.000236	CcSEcCtD
Salmeterol—Fatigue—Prednisone—prostate cancer	3.37e-05	0.000235	CcSEcCtD
Salmeterol—Nervousness—Doxorubicin—prostate cancer	3.37e-05	0.000235	CcSEcCtD
Salmeterol—Back pain—Doxorubicin—prostate cancer	3.35e-05	0.000234	CcSEcCtD
Salmeterol—Constipation—Prednisone—prostate cancer	3.34e-05	0.000233	CcSEcCtD
Salmeterol—Hypersensitivity—Docetaxel—prostate cancer	3.34e-05	0.000233	CcSEcCtD
Salmeterol—Muscle spasms—Doxorubicin—prostate cancer	3.33e-05	0.000232	CcSEcCtD
Salmeterol—Palpitations—Epirubicin—prostate cancer	3.31e-05	0.000231	CcSEcCtD
Salmeterol—Cough—Epirubicin—prostate cancer	3.27e-05	0.000228	CcSEcCtD
Salmeterol—Asthenia—Docetaxel—prostate cancer	3.25e-05	0.000227	CcSEcCtD
Salmeterol—Nausea—Etoposide—prostate cancer	3.24e-05	0.000226	CcSEcCtD
Salmeterol—Hypertension—Epirubicin—prostate cancer	3.24e-05	0.000226	CcSEcCtD
Salmeterol—Hypersensitivity—Capecitabine—prostate cancer	3.23e-05	0.000225	CcSEcCtD
Salmeterol—Feeling abnormal—Prednisone—prostate cancer	3.22e-05	0.000225	CcSEcCtD
Salmeterol—Ill-defined disorder—Doxorubicin—prostate cancer	3.22e-05	0.000224	CcSEcCtD
Salmeterol—Gastrointestinal pain—Prednisone—prostate cancer	3.2e-05	0.000223	CcSEcCtD
Salmeterol—Myalgia—Epirubicin—prostate cancer	3.19e-05	0.000222	CcSEcCtD
Salmeterol—Arthralgia—Epirubicin—prostate cancer	3.19e-05	0.000222	CcSEcCtD
Salmeterol—Chest pain—Epirubicin—prostate cancer	3.19e-05	0.000222	CcSEcCtD
Salmeterol—Agitation—Doxorubicin—prostate cancer	3.19e-05	0.000222	CcSEcCtD
Salmeterol—Anxiety—Epirubicin—prostate cancer	3.18e-05	0.000222	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.17e-05	0.000221	CcSEcCtD
Salmeterol—Discomfort—Epirubicin—prostate cancer	3.15e-05	0.00022	CcSEcCtD
Salmeterol—Asthenia—Capecitabine—prostate cancer	3.15e-05	0.00022	CcSEcCtD
Salmeterol—Malaise—Doxorubicin—prostate cancer	3.13e-05	0.000218	CcSEcCtD
Salmeterol—Dry mouth—Epirubicin—prostate cancer	3.12e-05	0.000217	CcSEcCtD
Salmeterol—Urticaria—Prednisone—prostate cancer	3.11e-05	0.000217	CcSEcCtD
Salmeterol—Diarrhoea—Docetaxel—prostate cancer	3.1e-05	0.000216	CcSEcCtD
Salmeterol—Abdominal pain—Prednisone—prostate cancer	3.09e-05	0.000215	CcSEcCtD
Salmeterol—Body temperature increased—Prednisone—prostate cancer	3.09e-05	0.000215	CcSEcCtD
Salmeterol—Palpitations—Doxorubicin—prostate cancer	3.06e-05	0.000214	CcSEcCtD
Salmeterol—Oedema—Epirubicin—prostate cancer	3.06e-05	0.000213	CcSEcCtD
Salmeterol—Anaphylactic shock—Epirubicin—prostate cancer	3.06e-05	0.000213	CcSEcCtD
Salmeterol—Infection—Epirubicin—prostate cancer	3.04e-05	0.000212	CcSEcCtD
Salmeterol—Cough—Doxorubicin—prostate cancer	3.03e-05	0.000211	CcSEcCtD
Salmeterol—Diarrhoea—Capecitabine—prostate cancer	3e-05	0.000209	CcSEcCtD
Salmeterol—Nervous system disorder—Epirubicin—prostate cancer	3e-05	0.000209	CcSEcCtD
Salmeterol—Dizziness—Docetaxel—prostate cancer	3e-05	0.000209	CcSEcCtD
Salmeterol—Hypertension—Doxorubicin—prostate cancer	2.99e-05	0.000209	CcSEcCtD
Salmeterol—Tachycardia—Epirubicin—prostate cancer	2.99e-05	0.000208	CcSEcCtD
Salmeterol—Skin disorder—Epirubicin—prostate cancer	2.97e-05	0.000207	CcSEcCtD
Salmeterol—Myalgia—Doxorubicin—prostate cancer	2.95e-05	0.000206	CcSEcCtD
Salmeterol—Arthralgia—Doxorubicin—prostate cancer	2.95e-05	0.000206	CcSEcCtD
Salmeterol—Chest pain—Doxorubicin—prostate cancer	2.95e-05	0.000206	CcSEcCtD
Salmeterol—Anxiety—Doxorubicin—prostate cancer	2.94e-05	0.000205	CcSEcCtD
Salmeterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.93e-05	0.000204	CcSEcCtD
Salmeterol—Discomfort—Doxorubicin—prostate cancer	2.92e-05	0.000203	CcSEcCtD
Salmeterol—Dizziness—Capecitabine—prostate cancer	2.9e-05	0.000202	CcSEcCtD
Salmeterol—Dry mouth—Doxorubicin—prostate cancer	2.89e-05	0.000201	CcSEcCtD
Salmeterol—Vomiting—Docetaxel—prostate cancer	2.88e-05	0.000201	CcSEcCtD
Salmeterol—Hypersensitivity—Prednisone—prostate cancer	2.88e-05	0.000201	CcSEcCtD
Salmeterol—Rash—Docetaxel—prostate cancer	2.86e-05	0.000199	CcSEcCtD
Salmeterol—Dermatitis—Docetaxel—prostate cancer	2.86e-05	0.000199	CcSEcCtD
Salmeterol—Headache—Docetaxel—prostate cancer	2.84e-05	0.000198	CcSEcCtD
Salmeterol—Oedema—Doxorubicin—prostate cancer	2.83e-05	0.000197	CcSEcCtD
Salmeterol—Anaphylactic shock—Doxorubicin—prostate cancer	2.83e-05	0.000197	CcSEcCtD
Salmeterol—Infection—Doxorubicin—prostate cancer	2.81e-05	0.000196	CcSEcCtD
Salmeterol—Asthenia—Prednisone—prostate cancer	2.81e-05	0.000196	CcSEcCtD
Salmeterol—Vomiting—Capecitabine—prostate cancer	2.79e-05	0.000195	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.79e-05	0.000194	CcSEcCtD
Salmeterol—Nervous system disorder—Doxorubicin—prostate cancer	2.78e-05	0.000193	CcSEcCtD
Salmeterol—Rash—Capecitabine—prostate cancer	2.77e-05	0.000193	CcSEcCtD
Salmeterol—Insomnia—Epirubicin—prostate cancer	2.77e-05	0.000193	CcSEcCtD
Salmeterol—Dermatitis—Capecitabine—prostate cancer	2.77e-05	0.000193	CcSEcCtD
Salmeterol—Tachycardia—Doxorubicin—prostate cancer	2.76e-05	0.000193	CcSEcCtD
Salmeterol—Headache—Capecitabine—prostate cancer	2.75e-05	0.000192	CcSEcCtD
Salmeterol—Skin disorder—Doxorubicin—prostate cancer	2.75e-05	0.000192	CcSEcCtD
Salmeterol—Paraesthesia—Epirubicin—prostate cancer	2.75e-05	0.000191	CcSEcCtD
Salmeterol—Dyspnoea—Epirubicin—prostate cancer	2.73e-05	0.00019	CcSEcCtD
Salmeterol—Nausea—Docetaxel—prostate cancer	2.69e-05	0.000188	CcSEcCtD
Salmeterol—Dyspepsia—Epirubicin—prostate cancer	2.69e-05	0.000188	CcSEcCtD
Salmeterol—Diarrhoea—Prednisone—prostate cancer	2.68e-05	0.000186	CcSEcCtD
Salmeterol—Fatigue—Epirubicin—prostate cancer	2.64e-05	0.000184	CcSEcCtD
Salmeterol—Pain—Epirubicin—prostate cancer	2.62e-05	0.000182	CcSEcCtD
Salmeterol—Constipation—Epirubicin—prostate cancer	2.62e-05	0.000182	CcSEcCtD
Salmeterol—Nausea—Capecitabine—prostate cancer	2.61e-05	0.000182	CcSEcCtD
Salmeterol—Dizziness—Prednisone—prostate cancer	2.59e-05	0.00018	CcSEcCtD
Salmeterol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.58e-05	0.00018	CcSEcCtD
Salmeterol—Insomnia—Doxorubicin—prostate cancer	2.56e-05	0.000178	CcSEcCtD
Salmeterol—Paraesthesia—Doxorubicin—prostate cancer	2.54e-05	0.000177	CcSEcCtD
Salmeterol—Dyspnoea—Doxorubicin—prostate cancer	2.52e-05	0.000176	CcSEcCtD
Salmeterol—Feeling abnormal—Epirubicin—prostate cancer	2.52e-05	0.000176	CcSEcCtD
Salmeterol—Gastrointestinal pain—Epirubicin—prostate cancer	2.5e-05	0.000174	CcSEcCtD
Salmeterol—Dyspepsia—Doxorubicin—prostate cancer	2.49e-05	0.000174	CcSEcCtD
Salmeterol—Vomiting—Prednisone—prostate cancer	2.49e-05	0.000173	CcSEcCtD
Salmeterol—Rash—Prednisone—prostate cancer	2.47e-05	0.000172	CcSEcCtD
Salmeterol—Dermatitis—Prednisone—prostate cancer	2.46e-05	0.000172	CcSEcCtD
Salmeterol—Headache—Prednisone—prostate cancer	2.45e-05	0.000171	CcSEcCtD
Salmeterol—Fatigue—Doxorubicin—prostate cancer	2.44e-05	0.00017	CcSEcCtD
Salmeterol—Urticaria—Epirubicin—prostate cancer	2.43e-05	0.000169	CcSEcCtD
Salmeterol—Pain—Doxorubicin—prostate cancer	2.42e-05	0.000169	CcSEcCtD
Salmeterol—Constipation—Doxorubicin—prostate cancer	2.42e-05	0.000169	CcSEcCtD
Salmeterol—Abdominal pain—Epirubicin—prostate cancer	2.42e-05	0.000169	CcSEcCtD
Salmeterol—Body temperature increased—Epirubicin—prostate cancer	2.42e-05	0.000169	CcSEcCtD
Salmeterol—Feeling abnormal—Doxorubicin—prostate cancer	2.33e-05	0.000163	CcSEcCtD
Salmeterol—Nausea—Prednisone—prostate cancer	2.32e-05	0.000162	CcSEcCtD
Salmeterol—Gastrointestinal pain—Doxorubicin—prostate cancer	2.31e-05	0.000161	CcSEcCtD
Salmeterol—Hypersensitivity—Epirubicin—prostate cancer	2.25e-05	0.000157	CcSEcCtD
Salmeterol—Urticaria—Doxorubicin—prostate cancer	2.25e-05	0.000157	CcSEcCtD
Salmeterol—Body temperature increased—Doxorubicin—prostate cancer	2.24e-05	0.000156	CcSEcCtD
Salmeterol—Abdominal pain—Doxorubicin—prostate cancer	2.24e-05	0.000156	CcSEcCtD
Salmeterol—Asthenia—Epirubicin—prostate cancer	2.19e-05	0.000153	CcSEcCtD
Salmeterol—Diarrhoea—Epirubicin—prostate cancer	2.09e-05	0.000146	CcSEcCtD
Salmeterol—Hypersensitivity—Doxorubicin—prostate cancer	2.08e-05	0.000145	CcSEcCtD
Salmeterol—Asthenia—Doxorubicin—prostate cancer	2.03e-05	0.000142	CcSEcCtD
Salmeterol—Dizziness—Epirubicin—prostate cancer	2.02e-05	0.000141	CcSEcCtD
Salmeterol—Vomiting—Epirubicin—prostate cancer	1.94e-05	0.000136	CcSEcCtD
Salmeterol—Diarrhoea—Doxorubicin—prostate cancer	1.94e-05	0.000135	CcSEcCtD
Salmeterol—Rash—Epirubicin—prostate cancer	1.93e-05	0.000134	CcSEcCtD
Salmeterol—Dermatitis—Epirubicin—prostate cancer	1.93e-05	0.000134	CcSEcCtD
Salmeterol—Headache—Epirubicin—prostate cancer	1.92e-05	0.000134	CcSEcCtD
Salmeterol—Dizziness—Doxorubicin—prostate cancer	1.87e-05	0.00013	CcSEcCtD
Salmeterol—Nausea—Epirubicin—prostate cancer	1.82e-05	0.000127	CcSEcCtD
Salmeterol—Vomiting—Doxorubicin—prostate cancer	1.8e-05	0.000125	CcSEcCtD
Salmeterol—Rash—Doxorubicin—prostate cancer	1.78e-05	0.000124	CcSEcCtD
Salmeterol—Dermatitis—Doxorubicin—prostate cancer	1.78e-05	0.000124	CcSEcCtD
Salmeterol—Headache—Doxorubicin—prostate cancer	1.77e-05	0.000124	CcSEcCtD
Salmeterol—Nausea—Doxorubicin—prostate cancer	1.68e-05	0.000117	CcSEcCtD
Salmeterol—ADRB2—Signaling Pathways—NGFR—prostate cancer	6.16e-06	9.4e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOA2—prostate cancer	6.1e-06	9.31e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAP3K7—prostate cancer	6.08e-06	9.29e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—HPGDS—prostate cancer	6.04e-06	9.22e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—TYMS—prostate cancer	6.03e-06	9.2e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2C19—prostate cancer	6e-06	9.16e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—GSTM1—prostate cancer	5.96e-06	9.09e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TNFRSF21—prostate cancer	5.91e-06	9.03e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ACHE—prostate cancer	5.85e-06	8.94e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTT1—prostate cancer	5.85e-06	8.94e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF10—prostate cancer	5.85e-06	8.93e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—LPL—prostate cancer	5.85e-06	8.93e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—SLC5A5—prostate cancer	5.82e-06	8.88e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2A6—prostate cancer	5.79e-06	8.84e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.76e-06	8.8e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTAP—prostate cancer	5.75e-06	8.78e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP7B1—prostate cancer	5.75e-06	8.78e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—JAK2—prostate cancer	5.71e-06	8.72e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—MAP2K1—prostate cancer	5.69e-06	8.68e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP2E1—prostate cancer	5.68e-06	8.67e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CD—prostate cancer	5.65e-06	8.62e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CYP1A1—prostate cancer	5.65e-06	8.62e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VAV3—prostate cancer	5.64e-06	8.62e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKR1C3—prostate cancer	5.63e-06	8.59e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NQO1—prostate cancer	5.62e-06	8.58e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SRD5A1—prostate cancer	5.61e-06	8.56e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SULT1E1—prostate cancer	5.61e-06	8.56e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—ERCC2—prostate cancer	5.6e-06	8.55e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PRKACB—prostate cancer	5.6e-06	8.55e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFBR2—prostate cancer	5.56e-06	8.49e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP17A1—prostate cancer	5.54e-06	8.46e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TH—prostate cancer	5.54e-06	8.45e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP3A4—prostate cancer	5.48e-06	8.36e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ITPR1—prostate cancer	5.47e-06	8.36e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.47e-06	8.35e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CB—prostate cancer	5.42e-06	8.28e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1B1—prostate cancer	5.39e-06	8.22e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ACSL4—prostate cancer	5.35e-06	8.16e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD17B3—prostate cancer	5.35e-06	8.16e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA2—prostate cancer	5.28e-06	8.06e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—MTHFR—prostate cancer	5.26e-06	8.04e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	5.23e-06	7.99e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GGT1—prostate cancer	5.22e-06	7.96e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	5.21e-06	7.95e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	5.18e-06	7.91e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PPARA—prostate cancer	5.16e-06	7.88e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NCOA1—prostate cancer	5.14e-06	7.84e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ARG2—prostate cancer	5.13e-06	7.83e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PHGDH—prostate cancer	5.13e-06	7.83e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UMPS—prostate cancer	5.13e-06	7.83e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP19A1—prostate cancer	5.06e-06	7.73e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—SLC5A5—prostate cancer	5.04e-06	7.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LDHB—prostate cancer	5.03e-06	7.68e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LPL—prostate cancer	5.02e-06	7.66e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	4.98e-06	7.6e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	4.97e-06	7.59e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP3A5—prostate cancer	4.94e-06	7.53e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	4.92e-06	7.52e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP2E1—prostate cancer	4.92e-06	7.51e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—RXRA—prostate cancer	4.89e-06	7.46e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NQO1—prostate cancer	4.87e-06	7.43e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CAV1—prostate cancer	4.86e-06	7.41e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	4.85e-06	7.4e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TH—prostate cancer	4.8e-06	7.32e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA3—prostate cancer	4.77e-06	7.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PDHA1—prostate cancer	4.77e-06	7.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TCN2—prostate cancer	4.77e-06	7.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—UCP3—prostate cancer	4.77e-06	7.28e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.76e-06	7.27e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP3A4—prostate cancer	4.74e-06	7.24e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	4.73e-06	7.22e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.72e-06	7.21e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—COMT—prostate cancer	4.71e-06	7.19e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	4.7e-06	7.18e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	4.69e-06	7.17e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTP1—prostate cancer	4.69e-06	7.15e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1B1—prostate cancer	4.66e-06	7.12e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ITPR1—prostate cancer	4.61e-06	7.04e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD3B1—prostate cancer	4.55e-06	6.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC22A3—prostate cancer	4.55e-06	6.94e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL2—prostate cancer	4.52e-06	6.9e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GGT1—prostate cancer	4.52e-06	6.9e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TERT—prostate cancer	4.51e-06	6.88e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NCOA1—prostate cancer	4.45e-06	6.79e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CG—prostate cancer	4.42e-06	6.75e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP19A1—prostate cancer	4.39e-06	6.7e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA4—prostate cancer	4.36e-06	6.66e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TBXAS1—prostate cancer	4.36e-06	6.66e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—TYMS—prostate cancer	4.36e-06	6.65e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	4.31e-06	6.58e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—GSTM1—prostate cancer	4.31e-06	6.57e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA2—prostate cancer	4.25e-06	6.49e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—RXRA—prostate cancer	4.23e-06	6.46e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—LPL—prostate cancer	4.23e-06	6.45e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—LEP—prostate cancer	4.21e-06	6.42e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.2e-06	6.41e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ABCG5—prostate cancer	4.2e-06	6.41e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—INS—prostate cancer	4.19e-06	6.39e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CAV1—prostate cancer	4.17e-06	6.36e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KDR—prostate cancer	4.12e-06	6.29e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.12e-06	6.29e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—CREBBP—prostate cancer	4.1e-06	6.26e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTA1—prostate cancer	4.1e-06	6.26e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CYP1A1—prostate cancer	4.08e-06	6.23e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—COMT—prostate cancer	4.08e-06	6.23e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTP1—prostate cancer	4.06e-06	6.2e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTO1—prostate cancer	4.05e-06	6.19e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.05e-06	6.19e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NAT2—prostate cancer	4.05e-06	6.19e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—ERCC2—prostate cancer	4.05e-06	6.18e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ESR1—prostate cancer	4.02e-06	6.13e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ITPR1—prostate cancer	3.99e-06	6.1e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.93e-06	5.99e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—BAD—prostate cancer	3.92e-06	5.98e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CD—prostate cancer	3.89e-06	5.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PLCB2—prostate cancer	3.89e-06	5.93e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2C18—prostate cancer	3.89e-06	5.93e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LRP2—prostate cancer	3.89e-06	5.93e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—P4HB—prostate cancer	3.81e-06	5.82e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—MTHFR—prostate cancer	3.81e-06	5.81e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	3.8e-06	5.8e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—APC—prostate cancer	3.8e-06	5.8e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—TYMS—prostate cancer	3.77e-06	5.76e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IRS1—prostate cancer	3.75e-06	5.73e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGF—prostate cancer	3.75e-06	5.73e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PPARA—prostate cancer	3.73e-06	5.7e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—GSTM1—prostate cancer	3.73e-06	5.69e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC22A1—prostate cancer	3.71e-06	5.66e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—NOS3—prostate cancer	3.67e-06	5.61e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—LPL—prostate cancer	3.66e-06	5.59e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	3.64e-06	5.56e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SULT2A1—prostate cancer	3.61e-06	5.51e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—INS—prostate cancer	3.59e-06	5.49e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MED12—prostate cancer	3.55e-06	5.43e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CYP1A1—prostate cancer	3.54e-06	5.4e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GNG5—prostate cancer	3.53e-06	5.38e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	3.52e-06	5.37e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CAV1—prostate cancer	3.51e-06	5.36e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—ERCC2—prostate cancer	3.51e-06	5.35e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IGF1—prostate cancer	3.48e-06	5.31e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	3.46e-06	5.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA3—prostate cancer	3.4e-06	5.19e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CB—prostate cancer	3.39e-06	5.17e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	3.36e-06	5.13e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTGS2—prostate cancer	3.36e-06	5.13e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	3.34e-06	5.09e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	3.31e-06	5.05e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	3.3e-06	5.04e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—MTHFR—prostate cancer	3.3e-06	5.03e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	3.27e-06	4.99e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—HPGDS—prostate cancer	3.24e-06	4.95e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PPARA—prostate cancer	3.23e-06	4.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.22e-06	4.92e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CG—prostate cancer	3.2e-06	4.88e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—FGF2—prostate cancer	3.19e-06	4.88e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—NOS3—prostate cancer	3.15e-06	4.81e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTT1—prostate cancer	3.14e-06	4.8e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ACHE—prostate cancer	3.14e-06	4.8e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.11e-06	4.74e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.06e-06	4.68e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CAV1—prostate cancer	3.04e-06	4.64e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—INS—prostate cancer	3.03e-06	4.62e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.02e-06	4.61e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PRKACB—prostate cancer	3.01e-06	4.59e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3e-06	4.58e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MDM2—prostate cancer	2.99e-06	4.56e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP17A1—prostate cancer	2.97e-06	4.54e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—CREBBP—prostate cancer	2.96e-06	4.53e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	2.95e-06	4.5e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PTEN—prostate cancer	2.93e-06	4.47e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	2.91e-06	4.44e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.9e-06	4.43e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA2—prostate cancer	2.83e-06	4.33e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CD—prostate cancer	2.81e-06	4.29e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	2.79e-06	4.27e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—EP300—prostate cancer	2.79e-06	4.26e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CG—prostate cancer	2.77e-06	4.23e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	2.73e-06	4.17e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.7e-06	4.13e-05	CbGpPWpGaD
Salmeterol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	2.7e-06	4.12e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CASP3—prostate cancer	2.68e-06	4.08e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL2—prostate cancer	2.67e-06	4.08e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—IL6—prostate cancer	2.66e-06	4.06e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—NOS3—prostate cancer	2.65e-06	4.05e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.64e-06	4.03e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—INS—prostate cancer	2.62e-06	4e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NQO1—prostate cancer	2.61e-06	3.99e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CCND1—prostate cancer	2.6e-06	3.98e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	2.58e-06	3.94e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TH—prostate cancer	2.57e-06	3.93e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—CREBBP—prostate cancer	2.57e-06	3.92e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MMP9—prostate cancer	2.53e-06	3.86e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	2.52e-06	3.85e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PTEN—prostate cancer	2.51e-06	3.84e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.5e-06	3.82e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CB—prostate cancer	2.45e-06	3.74e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CD—prostate cancer	2.43e-06	3.72e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTGS2—prostate cancer	2.43e-06	3.71e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GGT1—prostate cancer	2.42e-06	3.7e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EP300—prostate cancer	2.4e-06	3.66e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NCOA1—prostate cancer	2.39e-06	3.65e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.35e-06	3.59e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.33e-06	3.56e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—NOS3—prostate cancer	2.3e-06	3.51e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—RXRA—prostate cancer	2.27e-06	3.47e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.27e-06	3.47e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.25e-06	3.43e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—COMT—prostate cancer	2.19e-06	3.34e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTP1—prostate cancer	2.18e-06	3.33e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ITPR1—prostate cancer	2.14e-06	3.27e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CB—prostate cancer	2.12e-06	3.24e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PTEN—prostate cancer	2.12e-06	3.23e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTGS2—prostate cancer	2.1e-06	3.21e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.09e-06	3.19e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.08e-06	3.18e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—PIK3CA—prostate cancer	2.07e-06	3.15e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.04e-06	3.12e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—TYMS—prostate cancer	2.02e-06	3.09e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—EP300—prostate cancer	2.02e-06	3.08e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—GSTM1—prostate cancer	2e-06	3.06e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—LPL—prostate cancer	1.96e-06	3e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—KRAS—prostate cancer	1.93e-06	2.95e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.9e-06	2.9e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—ERCC2—prostate cancer	1.88e-06	2.87e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PTEN—prostate cancer	1.83e-06	2.8e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	1.77e-06	2.71e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—MTHFR—prostate cancer	1.77e-06	2.7e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—EP300—prostate cancer	1.75e-06	2.67e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PPARA—prostate cancer	1.74e-06	2.65e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—TP53—prostate cancer	1.72e-06	2.62e-05	CbGpPWpGaD
Salmeterol—CYP3A7—Metabolism—AKT1—prostate cancer	1.69e-06	2.58e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CAV1—prostate cancer	1.63e-06	2.49e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—IL6—prostate cancer	1.57e-06	2.4e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.49e-06	2.28e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.49e-06	2.27e-05	CbGpPWpGaD
Salmeterol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.45e-06	2.21e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—INS—prostate cancer	1.41e-06	2.15e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—CREBBP—prostate cancer	1.38e-06	2.1e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.31e-06	1.99e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.29e-06	1.97e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—NOS3—prostate cancer	1.23e-06	1.88e-05	CbGpPWpGaD
Salmeterol—CYP3A5—Metabolism—AKT1—prostate cancer	1.22e-06	1.86e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.14e-06	1.74e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTGS2—prostate cancer	1.13e-06	1.72e-05	CbGpPWpGaD
Salmeterol—CYP2C8—Metabolism—AKT1—prostate cancer	1.06e-06	1.61e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PTEN—prostate cancer	9.84e-07	1.5e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—EP300—prostate cancer	9.39e-07	1.43e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—PIK3CA—prostate cancer	6.94e-07	1.06e-05	CbGpPWpGaD
Salmeterol—CYP3A4—Metabolism—AKT1—prostate cancer	5.67e-07	8.66e-06	CbGpPWpGaD
